Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNF-α show improved pharmacokinetics and biological activity and reduced toxicity in mice

Journal of Immunotherapy

Volumn 20, Issue 3, 1997, Pages 180-193

  Kedar, Eli ^a   Palgi, Orna ^a   Golod, Galina ^a   Babai, Ilan ^a   Barenholz, Yechezkel ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

GM CSF; Liposomes; Mice; TNF

Indexed keywords

CYTOKINE; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LIPOSOME; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TARGETING; IMMUNOMODULATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MICROENCAPSULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CYTOKINES; DRUG CARRIERS; FEMALE; FIBROSARCOMA; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIESIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIPOSOMES; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECOMBINANT PROTEINS; SARCOMA, EXPERIMENTAL; SOLUBILITY; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031464145     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199705000-00003     Document Type: Article

References (52)

1. Lopez-Berestein G, Fidler IJ, eds. Liposomes in the therapy of infectious diseases and cancer. New York: Liss, 1989. (UCLA symposia on molecular and cellular biology, new series; vol 89).
2. Lasic DD. Liposomes: from physics to applications. Amsterdam: Elsevier, 1993.
3. Barenholz Y, Crommelin DJA. Liposomes as pharmaceutical dosage forms: In: Swarbrick J, Boylan EC, eds. Encyclopedia of pharmaceutical technology, vol 9. New York: Dekker, 1994:1-39.
4. Barenholz Y, Amselem S. Quality control assays in the development and clinical use of liposome based formulations. In: Gregoriadis G, ed. Liposome technology, 2nd ed. Boca Raton, Florida: CRC Press, 1993:527-616.
5. Asano T, Kleinerman ES. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. J Immunother 1993;14:286-92.
6. Anderson PM, Katsanis E, Leonard AS, et al. Increased local antitumor effects of interleukin-2 liposomes in mice with MCA-106 sarcoma pulmonary metastases. Cancer Res 1990; 50:1853-6.
7. Loeffler CM, Platt JL, Anderson PM. Antitumor effects of interleukin 2 liposomes and anti-CD3-stimulated T-cells against murine MCA-38 hepatic metastases. Cancer Res 1991;51:2127-32.
8. Anderson PM, Katsanis E, Sencer SF, Hasz D, Ochoa AC, Bostrom B. Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administration. J Immunother 1992;12:19-31.
9. Vaage J, Mayhew E. Immunotherapy of a mouse mammary carcinoma by sustained peritumor release of IL-2. Int J Cancer 1991;47:582-5.
10. Konno H, Mardo Y, Martin AF, et al. Effect of liposomal interleukin-2 on ascites-forming rat hepatoma. J Surg Oncol 1992;51:33-7.
11. Fidler IJ, Fogler WE, Kleinerman ES, Saiki I. Abrogation of species specificity for activation of tumoricidal properties in macrophages by recombinant mouse or human interferon encapsulated in liposomes. J Immunol 1985;135:4289-94.
12. Killion JJ, Fan D, Bucana CD, Frangos DN, Price JE, Fidler IJ. Augmentation of antiproliferative activity of interferon alpha against human bladder tumor cell lines by encapsulation of interferon alpha within liposomes. J Natl Cancer Inst 1989;81:1387-92.
13. Shin DM, Fidler IJ, Bucana CD, Fan D, Hong WK, Killion JJ. Superior antiproliferative effects mediated by interferon-α entrapped in liposomes against a newly established human lung cancer cell line. J Biol Response Mod 1990;9:355-60.
14. Debs RJ, Duzgunes N, Brunette EN, Fendly B, Patton J, Philip R. Liposome associated tumor necrosis factor retains bioactivity in the presence of neutralizing anti-tumor necrosis factor antibodies. J Immunol 1989;143:1192-7.
15. Debs RJ, Fuchs HJ, Philip R, et al. Immunomodulatory and toxic effects of free and liposome-encapsulated tumor necrosis factor-α in rats. Cancer Res 1990;50:375-80.
16. Nii A, Fan D, Fidler IJ. Cytotoxic potential of liposomes containing tumor necrosis factor-a against sensitive and resistant target cells. J Immunother 1991;10:13-9.
17. Anderson PM, Hanson D, Hasz DE, et al. Cytokines in liposomes: preliminary studies with IL-1, IL-2, IL-6, GM-CSF and interferon-y. Cytokine 1994;6:92-101.
18. Kedar E, Rutkowski Y, Braun E, Emanuel N, Barenholz Y. Delivery of cytokines by liposomes. I. Preparation and characterization of interleukin-2 encapsulated in long-circulating sterically stabilized liposomes. J Immunother 1994;16:47-59.
19. Kedar E, Braun E, Rutkowski Y, Emanuel N, Barenholz Y. Delivery of cytokines by liposomes. II. Interleukin-2 encapsulated in long-circulating sterically stabilized liposomes: immunomodulatory and anti-tumor activity in mice. J Immunother 1994;16:115-24.
20. Greenberger JS, Sakakeeny AM, Humphries RK, Eaves CJ, Eckner RJ. Demonstration of permanent factor-dependent multipotential (erythroid/neutrophil/basophil) hematopoietic progenitor cell lines. Proc Natl Acad Sci U S A 1983;80:2931-5.
21. Sher T, Rottem S, Gallily R. Mycoplasma capricolum membranes induce tumor necrosis factor α by a mechanism different from that of lipopolysaccharide. Cancer Immunol Immunother 1990,31:86-92.
22. Gillis S, Ferm MM, Ou W, Smith KA. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol 1978;120:2027-31.
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation in cytotoxicity assays. J Immunol Methods 1983;65:55-63.
24. Gruner SM, Lenk RP, Janoff AS, Ostro MJ. Novel multilayered lipid vesicles: comparison of physical characteristics of multilamellar liposomes and stable plurilamellar vesicles. Biochemistry 1985;24:2833-42.
25. Kirby C, Gregoriadis G. Dehydration-rehydration vesicles: a simple method for high yield entrapment in liposomes. Biotechnology 1984;November:979-84.
26. Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993;1151:201-15.
27. Stewart JC. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem 1980;104:486-9.
28. Lichtenberg D, Barenholz Y. Liposomes: preparation, characterization and preservation. In: Glick D, ed. Methods in biochemical analysis, vol 33. New York: Wiley, 1988:337-462.
29. Emanuel N, Kedar E, Toker O, Bolotin E, Barenholz Y. Steric stabilization of liposomes improves their use in diagnosis. In: Lasic DD, Barenholz Y. eds. Handbook of non-medical application of liposomes, vol 4. Boca Raton, Florida: CRC Press, 1996:229-43.
30. Emanuel N, Kedar E, Bolotin EM, Smorodinsky NI, Barenholz Y. Targeted delivery of doxorubicin via sterically stabilized immunoliposomes: pharmacokinetics and biodistribution in tumor-bearing mice. Pharm Res 1996;13:861-8.
31. Kedar E, Rezai AR, Giorgi JV, et al. Immunomodulatory effects in vitro of interleukin-2 and interferon-gamma on human blood and bone marrow mononuclear cells. Nat Immun Cell Growth Regul 1988;7:13-30.
32. Fiers W. Biological therapy with TNF: preclinical studies. In: DeVita VT, Hellman S, Rosenberg SA, eds. Biologic therapy of cancer, 2nd ed. Philadelphia: JB Lippincott, 1995:295-327.
33. Miller LL, Nagler CH. Granulocyte-stimulating factors. In: DeVita VT, Hellman S, Rosenberg SA, eds. Biologic therapy of cancer, 2nd ed. Philadelphia: JB Lippincott, 1995:141-82.
34. Hill ADK, Naama HA, Calvano SE, Daly JM. The effect of granulocyte-macrophage colony-stimulating factor on myeloid cells and its clinical applications. J Leukocyte Biol 1995; 58:634-42.
35. Fraker DL, Alexander HR, Pass HI. Biologic therapy with TNF: systemic administration and isolation perfusion. In: DeVita VT, Hellman S, Rosenberg SA. eds. Biologic therapy of cancer, 2nd ed. Philadelphia: JB Lippincott, 1995:329-45.
36. Lejeune FJ. High dose recombinant tumor necrosis factor (rTNFα) administered by isolation perfusion for advanced tumors of the limbs: a model for biochemotherapy of cancer. Eur J Cancer 1995;31A:1009-16.
37. Patterson TF, Andriole VT. The role of liposomal amphotericin B in the treatment of systemic fungal infections. Eur J Cancer Clin Oncol 1989:25:S63-8.
38. Davidson RN, Croft SL. Scott A, et al. Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet 1991; 337:1061-2.
39. Kleinerman ES, Fidler IJ. Systemic activation of macrophages by liposomes containing immunomodulators. In: DeVita VT, Hellman S, Rosenberg SA, eds. Biologic therapy of cancer, 2nd ed. Philadelphia: JB Lippincott, 1995:829-39.
40. Hengge UR, Brockmeyer NH, Baumann M, Reimann G, Goos M. Liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Lancet 1993;342:497.
41. Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995;13:1777-85.
42. Gause B, Longo DL, Janik J, et al. A phase I study of liposome-encapsulated IL-2 (LE-IL-2) [Abstract]. Proc Am Soc Clin Oncol 1993;12:293.
43. Liu D, ed. Forum: mechanism of liposome clearance. J Liposome Res 1996;6:1-140.
44. Onyeji CO, Nightingale CH, Tessier RR, Nicolau DP. Bow LN. Activities of clarithromycin, azithromycin, and ofloxacin in combination with liposomal or unencapsulated granulocyte-macrophage colony-stimulating factor against intramacrophage Mycobacterium avium-Mycobacterium intracellulare. J Infect Dis 1995;172:810-6.
45. Utsumi T, Hung M-H, Klostergaard J. Preparation and characterization of liposomal-lipophilic tumor necrosis factor. Cancer Res 1991;51:3362-6.
46. Yasui K, Fujioka H, Nakamura Y. Cryoprotective effect of gelatin and albumin on recombinant human tumor necrosis factor liposome. Chem Pharm Bull (Tokyo) 1993;41:2138-40.
47. Morishige H, Ohkuma T, Kaji A. In vitro cytostatic effect of TNF (tumor necrosis factor) entrapped in immunoliposomes on cells normally insensitive to TNF. Biochim Biophys Acta 1993;1151:59-68.
48. Weber F, Kremer C, Klinkhammer M, Rasier B, Brock M. Response of multicellular spheroids to liposomes containing TNF alpha. J Neurooncol 1994;18:217-24.
49. 2 in an anesthetized dog model. J Immunother 1995;17:19-29.
50. Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta 1992;1113:171-99.
51. Allen TM. Stealth liposomes: five years on. J Liposome Res 1992;2:321-34.
52. Lasic DD, Martin FJ, eds. Stealth liposomes. Boca Raton, Florida: CRC Press, 1995.